Non-alcoholic steatohepatitis progress in drug treatment.doc

 PAGE \* MERGEFORMAT 6 Non-alcoholic steatohepatitis progress in drug treatment Non-alcoholic fatty liver disease (NAFLD is the clear exception of alcohol and other factors caused by liver damage, in order to diffuse macrovesicular fatty liver cells into the main features of the clinical and pathological syndrome, including simple non-alcoholic fatty liver (NAFL and its evolution steatohepatitis (NASH and cirrhosis. Although NAFL probability of occurrence of NASH may be only 10% -20%, but 10 years may have 15% -25% of the NASH cirrhosis, 30 % -40% eventually die of liver disease. Although, NAFLD are still many aspects of the pathogenesis of the problem has not been elucidated, but the effective treatment of NASH in preventing the formation of cirrhosis has important clinical significance, and the study of drug treatment of fatty liver has become one of the hot areas. In this paper, in recent years about NASH Clinical Drug Review below. An insulin sensitizer Research data show that insulin resistance may be involved in non-alcoholic fatty liver disease and development of nonalcoholic steatohepatitis important factor in the formation. Day proposed to oxidative stress and lipid peroxidation as the center of the “two hits” theory that insulin resistance is caused by abnormal lipid metabolism fatty liver in the first blow. Therefore, drugs that improve insulin resistance in insulin-sensitizing agent may be an effective method of treatment of fatty liver. (1 double muscle drugs. class One of the mechanisms of drug to lower blood sugar is to improve insulin resistance, on behalf of drugs metformin. The drug can significantly enhance peripheral tissue sensitivity to insulin, and has some weight loss and the role of hyperinsulinemia. (2 thiazole TZDs drugs. The mechanism is to reduce the fat cells of free fatty acids (FFA and tumor necrosis factor (TNF-a release, an increase of glucose were used, while improving insulin sensitivity, regulating blood sugar an